showed that IFN-γ can induce Treg “fragility,” defined as loss of function ex vivo and loss of tumor tolerance in vivo, and that IFN-γ-induced Treg fragility is required for effective anti–PD-1 therapy in a colon adenocarcinoma model (53). Here, PDCD1 is linked to colon adenocarcinoma.